Jefferies 2012 Global Healthcare Conference Review

Datamonitor attended the Jefferies 2012 Global Healthcare Conference held in London over November 14–15, 2012.

This analysis review covers the key highlights of the conference:

Product-specific and overall company updates for: Aegerion, Cubist, Lundbeck, ImmunoGen, Medivation, Novo Nordisk, NPS

The status of late-stage agents such as Roche’s Perjeta (pertuzumab) for breast cancer, Novo Nordisk’s Tresiba (insulin degludec) and Ryzodeg (insulin degludec + insulin aspart) for type 2 diabetes, ImmunoGen’s trastuzumab emtansine (TDM1) for breast cancer, Rigel’s fostamatinib for rheumatoid arthritis, Aegerion’s lopidomide for homozygous familial hypercholesterolemia, NPS Pharmaceuticals’ Gattex (teduglutide) for short bowel syndrome and Natpara (recombinant human parathyroid hormone [1-84]) for the treatment of adult hypoparathyroidism, Cubist’s ceftolozane/tazobactam for complicated urinary tract infections and complicated intra-abdominal infections, and United Therapeutics’ implantable infusion.

Download our White Paper for the full analyst review.

This analysis review covers the key highlights of the conference:

Product-specific and overall company updates for: Aegerion, Cubist, Lundbeck, ImmunoGen, Medivation, Novo Nordisk, NPS

Download our White Paper for the full analyst review.

Download Whitepaper

Next steps

Request a Demo

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Request a free demo

How can we help you?

Our team is always happy to hear from you. Please call us at:

US Toll-Free : +1 888 670 8900
US Toll : +1 212-600-3520
UK & Europe : +44 (20) 805 20700

Or please submit your inquiry via the form so that we can provide you the best possible customer service.

Jefferies 2012 Global Healthcare Conference Review